Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Meegan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Medicinal Chemistry|September 17, 2011
Designed multiple ligands for cancer therapyN M O'Boyle, M J Meegan
Current Medicinal Chemistry|February 7, 2003
Advances in the science of estrogen receptor modulationM J Meegan, D G Lloyd
Current Medicinal Chemistry|August 5, 2008
Recent developments in the design of anti-depressive therapies: targeting the serotonin transporterS G Butler, M J Meegan
Current Cancer Drug Targets|May 16, 2009
Targeting tumors using estrogen receptor ligand conjugatesN O Keely, M J Meegan
Journal of Microencapsulation|July 1, 1989
Preparation and characterization of lactic/glycolic acid polymers and copolymersP B Deasy, M P Finan, M J Meegan
Drug and Chemical Toxicology|January 1, 1990
An evaluation of the acute in vivo toxicity of benzylidenechroman-4-ones, 1-thiobenzylidenechroman-4-ones and benzylidenetetralonesT M Al-Nakib, N J Miller, S Rashid, et al.
Anti-Cancer Drug Design|January 5, 2002
Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell lineM J Meegan, R B Hughes, D G Lloyd, et al.
Journal of Medicinal Chemistry|April 12, 2001
Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cellsM J Meegan, R B Hughes, D G Lloyd, et al.
European Journal of Medicinal Chemistry|December 17, 2013
Synthesis and antiproliferative action of a novel series of maprotiline analoguesY M McNamara, S A Bright, A J Byrne, et al.
Oncology Reports|March 22, 2019
Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markersS A Bright, A J Byrne, E Vandenberghe, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry|September 17, 2011
Designed multiple ligands for cancer therapyN M O'Boyle, M J Meegan
Current Medicinal Chemistry|February 7, 2003
Advances in the science of estrogen receptor modulationM J Meegan, D G Lloyd
Current Medicinal Chemistry|August 5, 2008
Recent developments in the design of anti-depressive therapies: targeting the serotonin transporterS G Butler, M J Meegan
Current Cancer Drug Targets|May 16, 2009
Targeting tumors using estrogen receptor ligand conjugatesN O Keely, M J Meegan
Journal of Microencapsulation|July 1, 1989
Preparation and characterization of lactic/glycolic acid polymers and copolymersP B Deasy, M P Finan, M J Meegan
Drug and Chemical Toxicology|January 1, 1990
An evaluation of the acute in vivo toxicity of benzylidenechroman-4-ones, 1-thiobenzylidenechroman-4-ones and benzylidenetetralonesT M Al-Nakib, N J Miller, S Rashid, et al.
Anti-Cancer Drug Design|January 5, 2002
Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell lineM J Meegan, R B Hughes, D G Lloyd, et al.
Journal of Medicinal Chemistry|April 12, 2001
Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cellsM J Meegan, R B Hughes, D G Lloyd, et al.
European Journal of Medicinal Chemistry|December 17, 2013
Synthesis and antiproliferative action of a novel series of maprotiline analoguesY M McNamara, S A Bright, A J Byrne, et al.
Oncology Reports|March 22, 2019
Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markersS A Bright, A J Byrne, E Vandenberghe, et al.
Pageof 2